Provided by Tiger Fintech (Singapore) Pte. Ltd.

BioAtla, Inc.

0.5077
+0.02585.35%
Post-market: 0.51780.0101+1.99%19:52 EDT
Volume:757.28K
Turnover:366.29K
Market Cap:29.66M
PE:-0.42
High:0.5100
Open:0.4800
Low:0.4687
Close:0.4819
Loading ...

Bioatla Inc - Plan to Finalize Phase 3 Trial Design in 2L+ Hpv+ Opscc With the U.S. Food and Drug Administration (FDA)

THOMSON REUTERS
·
02 Jun

Bioatla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in Hpv-Associated Oropharyngeal Squamous Cell Carcinoma (Hpv+ Opscc) at the 1.8 Mg/Kg Q2w Dosing Regimen

THOMSON REUTERS
·
02 Jun

BioAtla Receives Nasdaq Non-Compliance Notice

TIPRANKS
·
17 May

BioAtla Inc. Faces Nasdaq Delisting Threat Due to Failure to Meet Stockholders' Equity Requirement

Reuters
·
17 May

Bioatla Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
08 May

BioAtla Q1 EPS $(0.26) Beats $(0.31) Estimate

Benzinga
·
07 May

BRIEF-BioAtla Q1 Net Income USD -15.334 Million

Reuters
·
07 May

Bioatla Inc - Cash Balance Projected to Fund Operations Beyond 1H 2026

THOMSON REUTERS
·
07 May

Bioatla Inc expected to post a loss of 35 cents a share - Earnings Preview

Reuters
·
03 May

BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025

GlobeNewswire
·
29 Apr

BRIEF-BioAtla Announces Poster Presentations At The 2025 American Association For Cancer Research (Aacr) Annual Meeting

Reuters
·
24 Apr

BioAtla announces poster presentations at 2025 AACR meeting

TIPRANKS
·
24 Apr

Bioatla Announces Poster Presentations at the 2025 American Association for Cancer Research (Aacr) Annual Meeting

THOMSON REUTERS
·
24 Apr

BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire
·
23 Apr

BioAtla Is Maintained at Market Outperform by Citizens Capital Markets

Dow Jones
·
31 Mar

H.C. Wainwright Keeps Their Hold Rating on BioAtla (BCAB)

TIPRANKS
·
31 Mar

Positive Outlook for BioAtla: Strategic Moves and Promising Developments Signal Potential Upside

TIPRANKS
·
29 Mar

Q4 2024 Bioatla Inc Earnings Call

Thomson Reuters StreetEvents
·
29 Mar

Bioatla Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Mar

Bioatla Inc : Btig Cuts Target Price to $10 From $13

THOMSON REUTERS
·
28 Mar